# Possible underdiagnosis of ulcerative colitis in tertiary care can affect medication use and access to healthcare facilities

**Authors:** Sara Ferraro, Claudia Bartolini, Irma Convertino, Lorenzo Bertani, Francesco Costa, Emiliano Cappello, Olga Paoletti, Sabrina Giometto, Rosa Gini, Ersilia Lucenteforte, Marco Tuccori

PMC · DOI: 10.3389/fimmu.2026.1693891 · Frontiers in Immunology · 2026-02-10

## TL;DR

The study finds that missed ulcerative colitis diagnoses in hospitals lead to more emergency care and hospitalizations, even with similar treatments.

## Contribution

The study identifies a link between delayed UC diagnosis and increased healthcare utilization in tertiary care settings.

## Key findings

- 313 patients (8.3%) had prior GI-related visits suggesting a missed UC diagnosis.
- Missed diagnosis cases had higher rates of ED visits and hospitalizations.
- Despite similar treatment initiation, these patients faced increased urgent care needs.

## Abstract

Ulcerative colitis (UC) is a chronic inflammatory bowel disease where diagnostic delays can worsen the clinical outcomes and increase the strain on healthcare systems. This study investigated the frequency of potentially missed UC diagnoses in tertiary care and their impact on treatment patterns and healthcare utilization.

We conducted a retrospective cohort study using Tuscany’s regional healthcare database (2006–2020). Adults newly diagnosed with UC between 2011 and 2018 were included. A “possible missed diagnosis” was defined as a hospital or emergency department (ED) visit for gastrointestinal (GI) symptoms occurring 7–60 months before the UC diagnosis. We assessed the initiation of azathioprine and non-conventional therapies, as well as the rates of ED visits, hospital admissions, and surgery. Survival analyses and Cox regression models were applied.

Among 3,804 patients with UC, 313 (8.3%) had prior GI-related tertiary care visits suggestive of a missed diagnosis. The mean time to diagnosis was 27.5 months. Compared with those who were timely diagnosed, these patients were not more likely to start azathioprine or non-conventional therapies. However, subjects with a possible missed diagnosis had higher rates of ED visits [adjusted hazard ratio (aHR) = 1.8, 95%CI = 1.5–2.0], hospitalizations (aHR = 1.4, 95%CI = 1.2–1.7), and combined urgent care encounters (aHR = 1.5, 95%CI = 1.3–1.7) compared with other patients.

Patients with a potentially missed UC diagnosis are more likely to need emergency and inpatient care, despite receiving similar treatments. Promoting earlier recognition of UC symptoms in tertiary care may reduce avoidable hospital use and improve disease management.

## Linked entities

- **Chemicals:** azathioprine (PubChem CID 2265)
- **Diseases:** ulcerative colitis (MONDO:0005101)

## Full-text entities

- **Genes:** TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}
- **Diseases:** weight loss (MESH:D015431), ulcers of the (MESH:D014456), Crohn's and Colitis (MESH:D003424), COVID-19 (MESH:D000086382), death (MESH:D003643), colorectal cancer (MESH:D015179), ID (MESH:C566784), UC (MESH:D003093), IBD (MESH:D015212), rectal bleeding (MESH:D012002), abdominal pain (MESH:D015746), rectum (MESH:D012004), cancer-related disease (MESH:D009369), inflammation (MESH:D007249), gastrointestinal (GI) symptoms (MESH:D012817), diarrhea (MESH:D003967)
- **Chemicals:** vedolizumab (MESH:C543529), golimumab (MESH:C529000), azathioprine (MESH:D001379), tofacitinib (MESH:C479163), ustekinumab (MESH:D000069549), 5-aminosalicylic acid (MESH:D019804), infliximab (MESH:D000069285), adalimumab (MESH:D000068879)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12929424/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12929424/full.md

## References

27 references — full list in the complete paper: https://tomesphere.com/paper/PMC12929424/full.md

---
Source: https://tomesphere.com/paper/PMC12929424